We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $118.47 · 17 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart - Yahoo Finance
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart Yahoo Finance
Apogee Therapeutics shares surge following $1.3 billion Blackstone financing partnership (APOG) - MSN
Apogee Therapeutics shares surge following $1.3 billion Blackstone financing partnership (APOG) MSN
Latham & Watkins Advises Apogee Therapeutics in US$1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences, One of the Largest Life Sciences Financings of 2026 - Legal Desire Media and Insights
Latham & Watkins Advises Apogee Therapeutics in US$1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences, One of the Largest Life Sciences Financings of 2026 Legal Desire Media and Insights
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-05-30 Seeking Alpha
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | After market close (AMC) | $-0.89 | — | — | $15.38M | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Truist Securities | — | Maintain | Hold → Hold | — | Truist Securities: Hold |
| 2026. 05. 28. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 27. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 05. 01. | Rothschild & Co | — | Initiate coverage | — → Buy | — | Rothschild & Co: Buy |
| 2026. 03. 30. | Mizuho | — | Maintain | Outperform → Outperform | — | Mizuho: Outperform |
| 2026. 03. 25. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 281,386 | $23.68B | 0.02% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 105,241 | $7.94B | 0.01% | — | New position |